Curium's $8B Lantheus Buyout Gets Analyst Nod as 'Excellent Outcome'
LNTH has more than doubled off its 52-week low of $47.25 on elevated volume (5.3× avg).
Summary
Curium's definitive agreement to acquire Lantheus for up to $8 billion, or $114.50 per share including CVRs, is being hailed by William Blair as an 'excellent outcome' for shareholders. The analyst cites Lantheus' operational challenges and sees little chance of a competing bid, given the specialized nature of radiopharmaceuticals. The deal offers a 38% premium to the unaffected 60-day VWAP and combines Curium's therapeutics with Lantheus' diagnostics. This follows the earlier Dow Jones report confirming the merger; the analyst endorsement and deal structure details add conviction to the trade. Shares are up 2.37% to $102.00, near the $102.50 cash offer, suggesting the market sees limited upside from CVRs or a higher bid.
At the time of this announcement, LNTH was trading at $101.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $47.25 to $111.86. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.